The technology is built upon a foundation of a genetically engineered antibody-based biosensor that allows for detection within a matter of seconds after pathogen makes contact with the biosensor. learn more

The technology is currently being commercialized as BioFlash-Dx™ for the detection of human disease.The system enables rapid and affordable testing for a variety of markers associate with human diseases. learn more

12/5/11 — Signal Transduction Collaboration Dr. Graham Jack and his colleagues at IBI offer collaborative support in signal transduction studies for a proposal... read more

11/30/10 — IBI licenses its BioFlash-E™ technology to PathSensors, Inc.